- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial termination: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 13, 2023 P1, N=10, Terminated, Measures to enhance early detection of ILD have been introduced and steps to potentially reduce the occurrence of severe ILD include implementation of BSA Completed --> Terminated; Sponsor Decision
- |||||||||| Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis. (Pubmed Central) - Feb 10, 2023 Using PSMA, TFS was 16.9 and 9.9 months in the B-E and E-B arms, respectively (HR=0.491, 95% CI 0.253-0.952, P=0.031). These results suggested that when both bevacizumab and eribulin are administered, bevacizumab should be administered first and eribulin should be administered later to ensure the most effective use of each drug.
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal: Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives. (Pubmed Central) - Feb 10, 2023 These results suggested that when both bevacizumab and eribulin are administered, bevacizumab should be administered first and eribulin should be administered later to ensure the most effective use of each drug. No abstract available
- |||||||||| Votrient (pazopanib) / Novartis, Halaven (eribulin mesylate) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal: Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases. (Pubmed Central) - Feb 9, 2023 In addition, we also evaluate 19 patients selected other taxanes, 17 patients selected eribulin methylate, 11 patients pazopanib, and 2 patients selected nivolumab as second-line chemotherapy. The efficacy of a monthly docetaxel regimen is equivalent to a three-weekly paclitaxel regimen evaluated by Overall survival and DDT, even in the cohorts with metastasis, and it is a tolerable protocol for CAS as a maintenance therapy in the Japanese population.
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Scalp Cooling in MBC (clinicaltrials.gov) - Feb 8, 2023 P2, N=120, Recruiting, The efficacy of a monthly docetaxel regimen is equivalent to a three-weekly paclitaxel regimen evaluated by Overall survival and DDT, even in the cohorts with metastasis, and it is a tolerable protocol for CAS as a maintenance therapy in the Japanese population. Trial primary completion date: Jun 2023 --> Jun 2024
- |||||||||| Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 8, 2023 P1/2, N=106, Recruiting, Not yet recruiting --> Recruiting Suspended --> Recruiting | N=18 --> 106 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Trial completion date: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 8, 2023 P1, N=10, Completed, Suspended --> Recruiting | N=18 --> 106 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed | N=50 --> 10 | Trial completion date: Jul 2022 --> Mar 2022
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Halaven (eribulin mesylate) / Eisai, vinorelbine tartrate / Generic mfg.
Clinical, P3 data: 16/22 #TumorBoardTuesday 🔥Bonus🔥Mini tweetorial ✨TROPICS-02✨ 🔹Global, multi center, open-label 🔸phase III 🔹randomized 543 pts to sacituzumab govitecan (10 mg/kg days 1 & 8 every 21 days) vs physicians’ choice of chemo (eribulin, cap, gem, or vinorelbine) (Twitter) - Feb 7, 2023
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial initiation date, Combination therapy, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Feb 2, 2023 P2, N=30, Not yet recruiting, Even when complete resection would be difficult, multidisciplinary treatment including debulking surgery might be effective for disease control. Initiation date: Dec 2022 --> Mar 2023
- |||||||||| Halaven (eribulin mesylate) / Eisai
Characterising epithelial-to-mesenchymal transition in ovarian carcinosarcoma preclinical models to identify new targets for treatment () - Jan 13, 2023 - Abstract #LCC2023LCC_125; Interestingly, IM cells also exhibited increased sensitivity to eribulin mesylate, a chemotherapeutic known to reverse EMT2,4,5...This will identify signalling pathways that drive the sarcomatous transformation in OCS and the potential of targeting these genetic elements to disrupt OCS development will then be validated. Targeting these elements may result in a more epithelial tumour that exhibits increased susceptibility to standard first-line therapeutics, including chemotherapy.
- |||||||||| Halaven (eribulin mesylate) / Eisai
Journal: Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas. (Pubmed Central) - Jan 9, 2023 The combination of eribulin and gemcitabine was synergistic in L-sarcoma cultures and it showed to be active in in vivo studies. This combination deserves further exploration in the clinical context.
- |||||||||| Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Jan 9, 2023 P2, N=30, Recruiting, This combination deserves further exploration in the clinical context. Not yet recruiting --> Recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 29, 2022 P1/2, N=30, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Jun 2023
- |||||||||| Halaven (eribulin mesylate) / Eisai
Preclinical, Journal, IO biomarker: The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models. (Pubmed Central) - Dec 12, 2022 We further interrogated the combination of eribulin with ADU-S100 in the MMTV-PyVT spontaneous murine mammary tumor model where we observed significant antitumor efficacy with combination treatment. Together, our findings demonstrate that microtubule targeted chemotherapeutics have distinct immunological effects and that eribulin's ability to enhance innate immune sensing pathways supports its use in combination with immunotherapies, such as STING agonists, for the more effective treatment of TNBC and other malignancies.
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment closed, Trial primary completion date, Metastases: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Dec 8, 2022 P3, N=331, Active, not recruiting, This case report aims to emphasize the clinical value of a chronic chemotherapy treatment also in heavily pretreated and luminal-like metastatic breast cancer, supporting eribulin as a good choice to consider. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2023
- |||||||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment closed, Metastases: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov) - Dec 2, 2022 P3, N=725, Active, not recruiting, Data from this study support the central proposed premise suggesting that eribulin could be used as a CAF/matrix-normalizing drug. Recruiting --> Active, not recruiting
|